中国同辐(01763.HK)中期纯利升25.77%至1.48亿元
格隆汇8月30日丨中国同辐(01763.HK)公布,截至2019年6月30日止中期,实现收益人民币16.55亿元(单位下同),同比增长20.50%;毛利11.90亿元,同比增长971,63022.50%;公司权益股东应占期间利润1.48亿元,同比增长25.77%;每股盈利0.46元。
公告称,收益增加主要由于药品分部、放射源产品分部及独立医学检验实验室服务及其他业务的收益增加。毛利率由70.7%(经重列)增长至71.9%。毛利率上升主要是收入占比较大的药品分部的毛利率增加导致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.